Glaucoma Treatment Market, By Disease Type (Open-Angle Glaucoma, Angle Closure Glaucoma, Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region - Global Analysis Forecast Till 2030

The global glaucoma therapeutics market size was $6.29 Bn in 2019 & is projected to reach $10.15 Bn by 2030, exhibiting a CAGR of 6.81% in the forecast period.

Glaucoma is the leading cause of irreversible vision loss throughout the world. It refers to a group of diseases with varying risk factors, symptoms, treatment, and prognosis. Glaucoma is characterized by the loss of retinal ganglion cells (RGCs) and optic nerve axons, which results in an enlargement of the optical disc. This results in optic nerve damage and loss of the visual field.

Elevated intraocular pressure is a major risk factor for glaucoma  lowering IOP by 31 to 52% usually stops disease progression. As a result, new IOP-lowering glaucoma treatments have emerged. Although current treatments can slow the progression of glaucoma, they cannot reverse the disease's vision loss. 

Glaucoma, a chronic eye condition, necessitates prompt attention to prevent vision loss. With various glaucoma treatment options available, including glaucoma surgery and the use of glaucoma medicines, patients have hope for managing this condition effectively. Detecting glaucoma symptoms, such as blurred vision, eye pain, and gradual vision loss, is crucial in seeking timely treatment. While the causes of glaucoma may vary, increased intraocular pressure is a common factor. In cases where surgery is not required, glaucoma laser surgery can be a viable treatment option. It is essential to recognize and address both glaucoma symptoms and treatment to safeguard one's visual health.
 

Market Dynamics:

Drivers:

Government and pharmaceutical company activities to raise awareness of glaucoma are fueling the expansion of the glaucoma treatment market.
Another factor driving the expansion of the glaucoma treatment market is the technological development in eye drops, the most critical measure to combat glaucoma. Pharmaceutical and biotechnology companies are also investing in developing new glaucoma products. The most common drugs used today to treat glaucoma include alpha-adrenergic agonists, beta-blockers, carbonate anhydrase inhibitors, prostaglandin analogs, and combinations of these drugs.

Restrains:

Glaucoma is difficult to treat because it does not initially cause symptoms such as pain or vision loss. Glaucoma surgery also often leads to several post-operative problems. The lack of experienced healthcare professionals and knowledge of glaucoma treatment market in emerging areas may hinder the growth of the glaucoma treatment industry in the coming years.

Key players:

• Allergan

• Sun Pharma Advanced Research Company Limited,

• Santen Pharmaceutical Co., Ltd.,

• D.Western Therapeutics Institute (DWTI)

• Kowa Ltd.

• Alcon

• Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.

• Tear clear

• Peregrine Ophthalmic

• Envisia Therapeutics

• Ocuphire PharmaTeleflex

• Nicox OpthalmicsOphthalmicsarmaceuticals

• Perrigo Company

• Bausch and Lomb

• Ono Pharmaceutical

• Novartis, Merck & Co

• Aerie Pharmaceuticals and others

Market Segmentation:

By Disease Type:

• Open Angle Glaucoma

• Angle Closure Glaucoma

• Other

By Drug Class:

• Prostaglandin Analog

• Beta Blockers

• Adrenergic Agonist

• Carbonic Anhydrase Inhibitors

• Others

 Distribution Channel:

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

 Region:

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East & Africa

Regional Analysis

North America generated a revenue of $XX million in 2019. Well-equipped hospital infrastructure and efficient treatment framework for glaucoma diagnosis are key factors behind North America's dominance in this market. Failures develop slowly and can be detected quickly by effective diagnostic equipment. A favorable reimbursement scenario is expected to increase the adoption of glaucoma therapeutics in Europe. The National Health Service (NHS) in the United Kingdom (UK) has approved glaucoma medications as adjuvant treatment products for general use.

On the other hand, Asia Pacific is estimated to experience the highest growth in the market owing to the growing geriatric population in countries such as China and Japan. According to the World Bank, about 28% of Japan's population is over the age of 65. Finally, the Latin American, Middle Eastern, and African glaucoma treatment markets are quite small due to the limited availability of glaucoma diagnostic tools and low awareness of the disorder.

Scope of the Report:

User

Tab Content